Zura reports Phase 2 flop in painful skin disorder; stock nosedives

A small biotech’s stock collapsed after the company reported a Phase 2 failure in a debilitating skin condition. Zura Bio said Monday morning that both doses of its experimental drug tibulizumab fared no better than ...